(VIANEWS) – Sierra Bancorp (BSRR), Texas Roadhouse (TXRH), ACADIA Pharmaceuticals (ACAD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Sierra Bancorp (BSRR)
97.4% sales growth and 10.85% return on equity
Sierra Bancorp operates as the bank holding company for Bank of the Sierra that provides retail and commercial banking services to individuals and businesses in California. The company accepts various deposit products, such as checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. Its loan products include agricultural, commercial, consumer, real estate, construction, and mortgage loans. The company also offers automated teller machines; electronic point-of-sale payment alternatives; online and automated telephone banking services; and remote deposit capture and automated payroll services for business customers. As of December 31, 2021, it operated 35 full-service branches, an online branch, a loan production office, an agricultural credit center, and an SBA center. Sierra Bancorp was founded in 1977 and is headquartered in Porterville, California.
Earnings Per Share
As for profitability, Sierra Bancorp has a trailing twelve months EPS of $2.45.
PE Ratio
Sierra Bancorp has a trailing twelve months price to earnings ratio of 11.03. Meaning, the purchaser of the share is investing $11.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.85%.
Sales Growth
Sierra Bancorp’s sales growth is 8.9% for the present quarter and 97.4% for the next.
Yearly Top and Bottom Value
Sierra Bancorp’s stock is valued at $27.03 at 16:22 EST, way under its 52-week high of $31.85 and way above its 52-week low of $16.75.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 31, 2024, the estimated forward annual dividend rate is 0.96 and the estimated forward annual dividend yield is 3.55%.
2. Texas Roadhouse (TXRH)
20.1% sales growth and 31.96% return on equity
Texas Roadhouse, Inc., together with its subsidiaries, operates casual dining restaurants in the United States and internationally. The company operates and franchises Texas Roadhouse and Bubba's 33 restaurants. As of December 29, 2020, it operated 537 domestic restaurants and 97 franchise restaurants. Texas Roadhouse, Inc. was founded in 1993 and is based in Louisville, Kentucky.
Earnings Per Share
As for profitability, Texas Roadhouse has a trailing twelve months EPS of $5.52.
PE Ratio
Texas Roadhouse has a trailing twelve months price to earnings ratio of 31.45. Meaning, the purchaser of the share is investing $31.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.96%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 35.8% and 42.6%, respectively.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 12, 2024, the estimated forward annual dividend rate is 2.32 and the estimated forward annual dividend yield is 1.35%.
Previous days news about Texas Roadhouse(TXRH)
- According to Zacks on Wednesday, 14 August, "This helped Texas Roadhouse post Q2 sales of $1.34 billion which met estimates and rose 14% year over year. ", "To that point, Brinker International’s stock has soared +62% this year with Texas Roadhouse shares up nearly +40%."
- According to Zacks on Wednesday, 14 August, "To that point, Brinker has vastly outperformed the broader indexes and the Zacks Retail-Restaurants Market including two of its top industry peers in El Pollo Loco (LOCO Quick QuoteLOCO – Free Report) and Texas Roadhouse (TXRH Quick QuoteTXRH – Free Report) .", "Furthermore, EAT trades well below its Zacks Retail-Restaurants Industry average of 25X forward earnings with Texas Roadhouse at 26.9X and El Pollo Loco at 15.7X."
3. ACADIA Pharmaceuticals (ACAD)
10.8% sales growth and 6.7% return on equity
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ACADIA Pharmaceuticals has a trailing twelve months EPS of $0.19.
PE Ratio
ACADIA Pharmaceuticals has a trailing twelve months price to earnings ratio of 82.26. Meaning, the purchaser of the share is investing $82.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.7%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 135% and a drop 64.3% for the next.
Moving Average
ACADIA Pharmaceuticals’s value is under its 50-day moving average of $16.63 and way below its 200-day moving average of $20.92.
Revenue Growth
Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 890.53M for the twelve trailing months.
Yearly Top and Bottom Value
ACADIA Pharmaceuticals’s stock is valued at $15.63 at 16:22 EST, way under its 52-week high of $32.59 and above its 52-week low of $14.55.
4. STAAR Surgical Company (STAA)
8.6% sales growth and 4.18% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.31.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 133.94. Meaning, the purchaser of the share is investing $133.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.18%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 326.24M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 40% and a negative 43.3%, respectively.
Volume
Today’s last reported volume for STAAR Surgical Company is 508996 which is 11.12% below its average volume of 572724.
5. EZCORP (EZPW)
7.7% sales growth and 10.15% return on equity
EZCORP, Inc. provides pawn loans in the United States and Latin America. It offers pawn loans collateralized by tangible personal property, jewelry, consumer electronics, tools, sporting goods, and musical instruments. The company also sells merchandise, primarily collateral forfeited from pawn lending operations and pre-owned merchandise purchased from customers. In addition, it offers Lana and EZ+ web-based engagement platforms to manage pawn loans. As of September 30, 2021, the company owned and operated 516 pawn stores in the United States; 508 pawn stores in Mexico; and 124 pawn stores in Guatemala, El Salvador, and Honduras. EZCORP, Inc. was founded in 1989 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, EZCORP has a trailing twelve months EPS of $1.2.
PE Ratio
EZCORP has a trailing twelve months price to earnings ratio of 9.69. Meaning, the purchaser of the share is investing $9.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.15%.
Yearly Top and Bottom Value
EZCORP’s stock is valued at $11.62 at 16:22 EST, below its 52-week high of $11.75 and way above its 52-week low of $7.70.
Volume
Today’s last reported volume for EZCORP is 345984 which is 28.03% below its average volume of 480756.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10%, now sitting on 1.14B for the twelve trailing months.
Previous days news about EZCORP(EZPW)
- According to Zacks on Tuesday, 13 August, "Heritage Insurance (HRTG Quick QuoteHRTG – Free Report) , EZCORP (EZPW Quick QuoteEZPW – Free Report) , and Erie Indemnity (ERIE Quick QuoteERIE – Free Report) have all enjoyed positive price action over the last month, as illustrated below. ", "Several stocks have enjoyed market-beating price action over the last month, including Heritage Insurance (HRTG Quick QuoteHRTG – Free Report) , EZCORP (EZPW Quick QuoteEZPW – Free Report) , and Erie Indemnity (ERIE Quick QuoteERIE – Free Report) ."
